Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study

AKIFUMI KUWANO, MASAYOSHI YADA, KOSUKE TANAKA, TAIKAN HAMOMOTO, KAZUKI KUROSAKA, HIDEO SUZUKI and KENTA MOTOMURA
Anticancer Research October 2025, 45 (10) 4627-4636; DOI: https://doi.org/10.21873/anticanres.17808
AKIFUMI KUWANO
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: akuwnaoh1{at}aih-net.com
MASAYOSHI YADA
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
2Department of Gastroenterology, Ichinomiyanishi Hospital, Aichi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSUKE TANAKA
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAIKAN HAMOMOTO
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI KUROSAKA
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEO SUZUKI
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENTA MOTOMURA
1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 45 (10)
Anticancer Research
Vol. 45, Issue 10
October 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Ed Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
AKIFUMI KUWANO, MASAYOSHI YADA, KOSUKE TANAKA, TAIKAN HAMOMOTO, KAZUKI KUROSAKA, HIDEO SUZUKI, KENTA MOTOMURA
Anticancer Research Oct 2025, 45 (10) 4627-4636; DOI: 10.21873/anticanres.17808

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
AKIFUMI KUWANO, MASAYOSHI YADA, KOSUKE TANAKA, TAIKAN HAMOMOTO, KAZUKI KUROSAKA, HIDEO SUZUKI, KENTA MOTOMURA
Anticancer Research Oct 2025, 45 (10) 4627-4636; DOI: 10.21873/anticanres.17808
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Lenvatinib Suppresses Colorectal Cancer Cell Growth, Migration, and Invasion via Dual-pathway Apoptosis and ERK/STAT3/NF-{kappa}B Inactivation
  • Google Scholar

More in this TOC Section

  • Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance
  • Prognostic Difference According to the Site of Origin (Major vs. Minor) of Salivary Gland Carcinoma
  • Prognostic Significance of the Lymph Node Ratio in Obstructive Colorectal Cancer: A Retrospective Multicenter Study
Show more Clinical Studies

Keywords

  • Hepatocellular carcinoma
  • intermediate-stage
  • Atezolizumab plus bevacizumab
  • lenvatinib
  • cost-effectiveness
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire